BACKGROUND: Epidemiologic and genetic evidence links type 2 diabetes, obesity, and cancer. The tumor-suppressor phosphatase and tensin homologue (PTEN) has roles in both cellular growth and metabolic signaling. Germline PTEN mutations cause a cancer-predisposition syndrome, providing an opportunity to study the effect of PTEN haploinsufficiency in humans. METHODS: We measured insulin sensitivity and beta-cell function in 15 PTEN mutation carriers and 15 matched controls. Insulin signaling was measured in muscle and adipose-tissue biopsy specimens from 5 mutation carriers and 5 well-matched controls. We also assessed the effect of PTEN haploinsufficiency on obesity by comparing anthropometric indexes between the 15 patients and 2097 controls from a population-based study of healthy adults. Body composition was evaluated by means of dual-emission x-ray absorptiometry and skinfold thickness. RESULTS: Measures of insulin resistance were lower in the patients with a PTEN mutation than in controls (e.g., mean fasting plasma insulin level, 29 pmol per liter [range, 9 to 99] vs. 74 pmol per liter [range, 22 to 185]; P=0.001). This finding was confirmed with the use of hyperinsulinemic euglycemic clamping, showing a glucose infusion rate among carriers 2 times that among controls (P=0.009). The patients' insulin sensitivity could be explained by the presence of enhanced insulin signaling through the PI3K-AKT pathway, as evidenced by increased AKT phosphorylation. The PTEN mutation carriers were obese as compared with population-based controls (mean body-mass index [the weight in kilograms divided by the square of the height in meters], 32 [range, 23 to 42] vs. 26 [range, 15 to 48]; P<0.001). This increased body mass in the patients was due to augmented adiposity without corresponding changes in fat distribution. CONCLUSIONS: PTEN haploinsufficiency is a monogenic cause of profound constitutive insulin sensitization that is apparently obesogenic. We demonstrate an apparently divergent effect of PTEN mutations: increased risks of obesity and cancer but a decreased risk of type 2 diabetes owing to enhanced insulin sensitivity. (Funded by the Wellcome Trust and others.).
BACKGROUND: Epidemiologic and genetic evidence links type 2 diabetes, obesity, and cancer. The tumor-suppressor phosphatase and tensin homologue (PTEN) has roles in both cellular growth and metabolic signaling. Germline PTEN mutations cause a cancer-predisposition syndrome, providing an opportunity to study the effect of PTEN haploinsufficiency in humans. METHODS: We measured insulin sensitivity and beta-cell function in 15 PTEN mutation carriers and 15 matched controls. Insulin signaling was measured in muscle and adipose-tissue biopsy specimens from 5 mutation carriers and 5 well-matched controls. We also assessed the effect of PTEN haploinsufficiency on obesity by comparing anthropometric indexes between the 15 patients and 2097 controls from a population-based study of healthy adults. Body composition was evaluated by means of dual-emission x-ray absorptiometry and skinfold thickness. RESULTS: Measures of insulin resistance were lower in the patients with a PTEN mutation than in controls (e.g., mean fasting plasma insulin level, 29 pmol per liter [range, 9 to 99] vs. 74 pmol per liter [range, 22 to 185]; P=0.001). This finding was confirmed with the use of hyperinsulinemic euglycemic clamping, showing a glucose infusion rate among carriers 2 times that among controls (P=0.009). The patients' insulin sensitivity could be explained by the presence of enhanced insulin signaling through the PI3K-AKT pathway, as evidenced by increased AKT phosphorylation. The PTEN mutation carriers were obese as compared with population-based controls (mean body-mass index [the weight in kilograms divided by the square of the height in meters], 32 [range, 23 to 42] vs. 26 [range, 15 to 48]; P<0.001). This increased body mass in the patients was due to augmented adiposity without corresponding changes in fat distribution. CONCLUSIONS: PTEN haploinsufficiency is a monogenic cause of profound constitutive insulin sensitization that is apparently obesogenic. We demonstrate an apparently divergent effect of PTEN mutations: increased risks of obesity and cancer but a decreased risk of type 2 diabetes owing to enhanced insulin sensitivity. (Funded by the Wellcome Trust and others.).
Authors: M Stumvoll; A Mitrakou; W Pimenta; T Jenssen; H Yki-Järvinen; T Van Haeften; W Renn; J Gerich Journal: Diabetes Care Date: 2000-03 Impact factor: 19.112
Authors: S Iida; A Ono; K Sayama; T Hamaguchi; H Fujii; H Nakajima; M Namba; T Hanafusa; Y Matsuzawa; K Moriwaki Journal: Anticancer Res Date: 2000 May-Jun Impact factor: 2.480
Authors: Bangyan Stiles; Ying Wang; Andreas Stahl; Sara Bassilian; W Paul Lee; Yoon-Jung Kim; Robert Sherwin; Sherin Devaskar; Ralf Lesche; Mark A Magnuson; Hong Wu Journal: Proc Natl Acad Sci U S A Date: 2004-02-09 Impact factor: 11.205
Authors: R K Semple; M A Soos; J Luan; C S Mitchell; J C Wilson; M Gurnell; E K Cochran; P Gorden; V K K Chatterjee; N J Wareham; S O'Rahilly Journal: J Clin Endocrinol Metab Date: 2006-05-16 Impact factor: 5.958
Authors: Kevin C Corbit; João Paulo G Camporez; Jennifer L Tran; Camella G Wilson; Dylan A Lowe; Sarah M Nordstrom; Kirthana Ganeshan; Rachel J Perry; Gerald I Shulman; Michael J Jurczak; Ethan J Weiss Journal: JCI Insight Date: 2017-02-09
Authors: Ana Ortega-Molina; Elena Lopez-Guadamillas; Julie A Mattison; Sarah J Mitchell; Maribel Muñoz-Martin; Gema Iglesias; Vincent M Gutierrez; Kelli L Vaughan; Mark D Szarowicz; Ismael González-García; Miguel López; David Cebrián; Sonia Martinez; Joaquin Pastor; Rafael de Cabo; Manuel Serrano Journal: Cell Metab Date: 2015-03-26 Impact factor: 27.287
Authors: David Garcia-Galiano; Beatriz C Borges; Jose Donato; Susan J Allen; Nicole Bellefontaine; Mengjie Wang; Jean J Zhao; Kenneth M Kozloff; Jennifer W Hill; Carol F Elias Journal: JCI Insight Date: 2017-12-07
Authors: David A Bulger; Jermaine Conley; Spencer H Conner; Gipsy Majumdar; Solomon S Solomon Journal: Biochem Biophys Res Commun Date: 2015-04-24 Impact factor: 3.575